Corvus Pharmaceuticals Inc. (CRVS) Upgraded by Zacks Investment Research to Hold
Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Monday.
According to Zacks, “Corvus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of immuno-oncology therapies to harness the immune system to attack cancer cells. Its products include CPI-444, Adenosine production inhibitor, Adenosine A2B antagonist and Interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. Corvus Pharmaceuticals, Inc. is based in Burlingame, California. “
A number of other research firms have also commented on CRVS. Cantor Fitzgerald set a $23.00 price target on Corvus Pharmaceuticals and gave the company a “buy” rating in a research report on Saturday, August 6th. Credit Suisse Group AG reaffirmed a “buy” rating and set a $25.00 price target on shares of Corvus Pharmaceuticals in a research report on Tuesday, September 27th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Corvus Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $21.60.
Corvus Pharmaceuticals (NASDAQ:CRVS) traded down 0.49% on Monday, hitting $16.37. The stock had a trading volume of 19,106 shares. The company’s market cap is $342.28 million. Corvus Pharmaceuticals has a 1-year low of $9.63 and a 1-year high of $17.77. The stock has a 50 day moving average price of $14.81 and a 200 day moving average price of $13.98.
Several hedge funds and other institutional investors have recently bought and sold shares of CRVS. FMR LLC increased its position in Corvus Pharmaceuticals by 5.3% in the second quarter. FMR LLC now owns 2,311,297 shares of the company’s stock worth $32,959,000 after buying an additional 116,500 shares during the period. Jennison Associates LLC increased its position in Corvus Pharmaceuticals by 22.9% in the second quarter. Jennison Associates LLC now owns 570,481 shares of the company’s stock worth $8,067,000 after buying an additional 106,349 shares during the period. BlackRock Advisors LLC increased its position in Corvus Pharmaceuticals by 437.2% in the second quarter. BlackRock Advisors LLC now owns 456,117 shares of the company’s stock worth $6,504,000 after buying an additional 371,217 shares during the period. Scopia Capital Management LP purchased a new position in Corvus Pharmaceuticals during the first quarter worth $3,096,000. Finally, JPMorgan Chase & Co. purchased a new position in Corvus Pharmaceuticals during the second quarter worth $2,497,000. Hedge funds and other institutional investors own 82.91% of the company’s stock.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on the development of agents, which target the immune system to treat patients with cancer. The Company is developing drugs and antibodies that block crucial immune checkpoints, and reprogram immune T-cells.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Corvus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.